View Older Stories View More Recent Stories
-
Abbvie (ABBV) PT Raised to $284 at Piper Sandler
-
Abbvie (ABBV) PT raised to $250 at Cantor Fitzgerald on Skyrizi, Vyalev gains
-
Aldeyra Therapeutics (ALDX) PT Raised to $7 at Jefferies
-
AbbVie reports $2.7 billion IPR&D expense to impact Q3 earnings
-
AbbVie (ABBV) call put ratio 2.8 calls to 1 put with a focus on November 210 calls
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
AbbVie starts $70 million expansion at Massachusetts biologics facility
-
AbbVie submits FDA application for rare blood cancer treatment
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
AbbVie breaks ground on $195 million Illinois manufacturing facility
-
AbbVie sets UK price for ovarian cancer drug ELAHERE equal to US rate
-
AbbVie submits FDA application for parkinson's drug tavapadon
-
Abbvie (ABBV) PT Raised to $243 at Leerink Partners
-
Allergan Aesthetics expands SKINVIVE to 35 new markets globally
-
Raymond James: 'LinkedIn posts from executives at AbbVie indicate that the company has selected Salesforce for its future CRM'
-
Berenberg Upgrades Abbvie (ABBV) to Buy
-
Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $240 at BMO Capital
-
AbbVie (ABBV) Declares $1.64 Quarterly Dividend; 3.1% Yield
-
Raymond James Reiterates Outperform Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $215 at Cantor Fitzgerald
-
AbbVie invests $195 million in US manufacturing facility expansion
-
Piper Sandler Assumes Abbvie (ABBV) at Overweight
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Bernstein Reiterates Market Perform Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $227 at Guggenheim
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
AbbVie (ABBV) Tops Q2 EPS by 1c; raises guidance
-
Stocks expected to have increasing option volume: ABBV CMCSA BMY RBLX CI CVS K BIIB NCLH ARM MSTR PPC
-
AbbVie earnings preview Q2: set for flat quarter with guidance, M&A in focus
-
AbbVie (ABBV) call put ratio 2.3 calls to 1 put with a focus on January 230 calls into quarter results
-
AbbVie licenses cancer drug ISB 2001 from IGI for up to $1.925 billion
-
AbbVie licenses multiple myeloma drug from IGI for $700 million upfront
-
JPMorgan Reiterates Overweight Rating on Abbvie (ABBV)
-
AbbVie (ABBV) Issues Q2 and FY25 Guidance
-
Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
-
AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion
-
AbbVie (ABBV) Announces FDA's Acceptance of Allergan's Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM
-
AbbVie (ABBV) Declares $1.64 Quarterly Dividend; 3.5% Yield
-
AbbVie (ABBV) Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
-
Trump Administration Said To Consider Crackdown On Pharma Ads - Bloomberg
-
AbbVie (ABBV) Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
-
Sens. Sanders and King Co-Sponsor Bill to End Pharma Ads to Consumers -- WSJ
-
AbbVie (ABBV): U.S. FDA Approves Expanded Indication for MAVYRET as First and Only Treatment for People with Acute Hepatitis C Virus
-
Abbvie (ABBV) PT Lowered to $170 at Berenberg
-
AbbVie (ABBV) Announces FDA Approval of EMRELIS for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer With High c-Met Protein Overexpression
-
AbbVie, Merck cut to Neutral at Citi
-
AbbVie (ABBV) and ADARx Pharmaceuticals Enter Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
-
Citi Downgrades Abbvie (ABBV) to Neutral
